Kfar Saba, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announces preliminary unaudited results for the six months ended June 30, 2025. The Company’s revenues for the six months ended June 30, 2025, are expected to amount to approximately $350,000 compared to $283,000 for the six months ended June 30, ...

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully produced over 250 kilograms of reeled raw recombinant spider silk using automated equipment, setting a new single run record and enhancing quality, yield, and scalability of production [1][4][5] Group 1: Production Improvements - The use of automated reeling equipment allows for fine-tuning the reeling process specifically for spider silk, optimizing fiber consistency and maximizing silk output [3][4] - Automated reeling replaces conventional multi-end systems, significantly improving throughput, labor efficiency, and downstream silk quality [4] Group 2: Strategic Developments - Recent operational momentum includes the expansion of rearing capacity in Asia and the development of new spider silk strains, supporting the mission to bring eco-friendly spider silk fibers to market [5][7] - The compatibility of Kraig Labs' proprietary spider silk cocoons with advanced reeling systems is central to building a vertically integrated production model for spider silk at scale [4][5]

Core Insights - OraSure Technologies, Inc. has appointed Anne Messing as Chief Commercial Officer, bringing over 25 years of experience in the healthcare industry [1][2] - Ms. Messing will oversee Sales, Marketing, Strategic Alliances, and Product Management, aiming to enhance OTI's market leadership and long-term growth [2][4] - The company focuses on improving healthcare access, quality, and value through innovative diagnostic tests and sample management solutions [5] Company Background - OraSure Technologies is a leader in point-of-need and home diagnostic tests, as well as sample management solutions [1][5] - The company, along with its subsidiaries, develops and distributes rapid diagnostic tests and sample collection devices globally [5] - OTI's products are utilized by various sectors, including clinical laboratories, hospitals, and direct consumers [5] Leadership Experience - Prior to joining OTI, Ms. Messing held a significant role at Becton Dickinson, where she led initiatives that exceeded market benchmarks [3] - Her extensive background includes leadership positions at Danaher, Quest Diagnostics, Siemens Healthcare Diagnostics, and ARUP Laboratories [3] - Ms. Messing has a strong foundation in healthcare, starting her career as a certified medical technologist [3] Strategic Vision - The company aims to leverage Ms. Messing's expertise to drive growth and deliver exceptional value to stakeholders [4] - OTI is preparing for impactful product launches as part of its strategic vision for the future [4]

Core Points - The Kingdom of Tonga and TMC's subsidiary, Tonga Offshore Mining Ltd (TOML), signed a revised Sponsorship Agreement, updating the terms of their 2021 agreement [1][9] - The updated agreement ensures that Tonga will continue to receive financial benefits, training, and community programs while securing continuity benefits upon the commencement of commercial production [2][8] - Tonga has played a leading role in the development of the seafloor minerals industry and is committed to responsible mining practices [4][5] Company and Industry Summary - TMC is a leading developer of critical metals essential for energy, defense, manufacturing, and infrastructure, focusing on lower-impact extraction from seafloor polymetallic nodules [1][10] - The agreement highlights Tonga's commitment to transparency, fairness, and environmental care in seabed mineral activities, aligning with its long-term development goals [4][6] - The International Seabed Authority (ISA) has faced delays in adopting Exploitation Regulations, impacting TOML's ability to proceed with commercial exploitation activities [9]

Core Viewpoint - Elme Communities has entered into a Purchase and Sale Agreement with Cortland Partners to sell a 19-asset portfolio for $1.6 billion, initiating a plan for voluntary liquidation and asset sales to maximize shareholder value [1][2][3] Financial Distributions - The company plans to make total upfront distributions to shareholders of approximately $14.68 to $15.00 per share, assuming the completion of the Cortland Portfolio Transaction [1][6] - Additional liquidating distributions are estimated to be approximately $2.90 to $3.50 per share from the sale of remaining assets [1][6] Transaction Details - The Portfolio Sale Transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and customary closing conditions [1][11] - The company will market its remaining nine multifamily assets and Watergate 600 for sale within the next 12 months [2][11] Strategic Review Process - The decision to proceed with the sale and liquidation followed a comprehensive evaluation of strategic alternatives, including engagement with over 80 potential counterparties [3][11] - The Board of Trustees unanimously determined that the sale to Cortland and subsequent asset sales would yield the highest value for shareholders compared to other options [3][11] Future Operations - Following the completion of the Portfolio Sale Transaction, the company expects to suspend regular quarterly distributions and focus on liquidating distributions from future asset sales [10][11] - The company has received a debt commitment of $520 million from Goldman Sachs Bank USA to finance assets not included in the Portfolio Sale Transaction [9] Market Presence - The transaction marks Cortland's significant expansion in the greater Washington, D.C. area and Georgia, enhancing its portfolio and operational capabilities [3][4]

Core Insights - BioNTech reported significant advancements in its oncology strategy, including collaborations and acquisitions aimed at enhancing its product pipeline and capabilities [2][6][30] - The company experienced a substantial increase in revenues for the second quarter of 2025, driven primarily by its COVID-19 vaccine collaboration [3][4] - BioNTech's financial position remains strong, with substantial cash reserves and expected cash inflows from strategic partnerships [10][11][14] Financial Performance - Revenues for Q2 2025 reached €260.8 million, up from €128.7 million in Q2 2024, while total revenues for the first half of 2025 were €443.6 million compared to €316.3 million in the prior year [3][4] - The net loss for Q2 2025 was €386.6 million, a significant reduction from a net loss of €807.8 million in Q2 2024, with a total net loss of €802.4 million for the first half of 2025 compared to €1,122.9 million in the same period last year [7][8] - Basic and diluted loss per share improved to €1.60 for Q2 2025 from €3.36 in Q2 2024, and for the first half of 2025, it was €3.33 compared to €4.67 in the prior year [8][41] Research and Development - R&D expenses for Q2 2025 were €509.1 million, down from €584.6 million in Q2 2024, with total R&D expenses for the first half of 2025 at €1,034.7 million compared to €1,092.1 million in the previous year [4][5] - The company is focusing on its oncology pipeline, including the development of BNT327, a bispecific antibody candidate, and has initiated several clinical trials for various cancer treatments [6][23][27] Strategic Developments - BioNTech entered a collaboration with Bristol Myers Squibb (BMS) for the co-development of BNT327, which includes an upfront cash payment of $1.5 billion and potential milestone payments totaling up to $7.6 billion [10][11][12] - The acquisition of CureVac is expected to enhance BioNTech's capabilities in mRNA technology, complementing its existing product offerings [2][6][30] - The company has received approval for a new variant-adapted COVID-19 vaccine, with preparations for launch underway [6][22] Financial Guidance - BioNTech reaffirmed its revenue guidance for the full year 2025, expecting revenues to be between €1,700 million and €2,200 million, with a focus on late-stage development and commercialization in oncology [14][16] - Planned expenses for 2025 include R&D expenses of €2,600 million to €2,800 million and SG&A expenses of €650 million to €750 million [15][16]

Anchorage Alaska, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) ) is pleased to announce results from the ongoing RPM gold feasibility metallurgical test work program, which is showing exceptional recoveries in our opinion, with potential further opportunities to optimize for even higher recoveries. Highlights RPM conceptual flowsheet outlines clear path to high gold recoveries (Figure 6).High-grade ore over 2 g/t Au fed directly into t ...

Delivers Category Leading GrowthDrives Operational Efficiencies that Deliver Margin Expansion and Reduce Capital RequirementsUpdates Outlook for 2025 and 2027 BEDMINSTER, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its second quarter and six months ended June 30, 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $264.7 million, an increase of 12.5%.Net income of $16.4 million, ...

CHICAGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced a 1-for-20 reverse stock split of its Class A and Class B common stock (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on August 5, 2025. The Class A common stock will begin trading on the Nasdaq Global Select Mark ...

Core Insights - SiriusPoint Ltd. reported strong second quarter results, highlighting the effectiveness of its disciplined underwriting strategy, with an underlying return on equity of 17.0% for the quarter and 15.4% for the half year, both exceeding the target range of 12-15% [1][5][6] Financial Performance - The Core combined ratio for the second quarter was 89.5%, improving by 3.8 points year-over-year, while the half-year Core combined ratio remained flat despite increased volatility from aviation losses and wildfires [2][5] - Gross premiums written increased by 10% year-over-year, reaching $930.1 million for the second quarter, marking the fifth consecutive quarter of double-digit growth [2][14] - Underwriting income for the Core business grew by 83% year-over-year to $68 million in the second quarter [5][15] - Diluted earnings per common share were $0.50, with underlying earnings per share of $0.66, representing a 120% increase from the prior year [5][6] Segment Performance - The Insurance & Services segment generated gross premiums written of $560.4 million for the second quarter, a 14.3% increase compared to the same period last year, driven by growth in Surety and A&H [22][23] - The Reinsurance segment saw gross premiums written of $369.7 million for the second quarter, an increase of 4.9% year-over-year, primarily due to increased premiums in credit [28][29] Investment Results - Net investment income for the second quarter was $68.2 million, with total investment results reaching $68.9 million [6][33] - The company experienced a year-over-year increase in net investment income and net realized and unrealized investment gains, recovering from losses on strategic investments in the previous year [33][34] Operational Highlights - SiriusPoint was recognized as Program Insurer of the Year in the US and achieved record scores in its employee engagement survey, indicating strong organizational momentum [3][5] - The company attracted key talent to its executive leadership team, further enhancing its operational capabilities [3]